StreetInsider.com News Articles

Form 424B3 Jaguar Health, Inc.

Mon, 27 Jul 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260727/26816385.html

Form 424B3 Jaguar Health, Inc.

Mon, 27 Jul 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260727/26816385.html

Form 424B3 Jaguar Health, Inc.

Mon, 27 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260727/26816333.html

Form 424B3 Jaguar Health, Inc.

Mon, 27 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260727/26816333.html

Form EFFECT Jaguar Health, Inc.

Mon, 27 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260727/26815425.html

Form EFFECT Jaguar Health, Inc.

Mon, 27 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260727/26815425.html

Form EFFECT Jaguar Health, Inc.

Mon, 27 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260727/26815427.html

Form EFFECT Jaguar Health, Inc.

Mon, 27 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260727/26815427.html

Form PRE 14A Jaguar Health, Inc. For: Sep 04

Fri, 24 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260724/26813710.html

Form PRE 14A Jaguar Health, Inc. For: Sep 04

Fri, 24 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260724/26813710.html

Jaguar Health (JAGX) files for 41M share offering by selling stockholders

Fri, 24 Jul 2026 14:01:27 -0400

Jaguar Health (NASDAQ: JAGX) filed for up to 41,000,000 share offering by selling stockholders.

Jaguar Health (JAGX) files for 41M share offering by selling stockholders

Fri, 24 Jul 2026 14:01:27 -0400

Jaguar Health (NASDAQ: JAGX) filed for up to 41,000,000 share offering by selling stockholders.

Form S-1/A Jaguar Health, Inc.

Fri, 24 Jul 2026 13:59:00 -0400

si-local-file:///var/storage/secattach/20260724/26812918.html

Form S-1/A Jaguar Health, Inc.

Fri, 24 Jul 2026 13:59:00 -0400

si-local-file:///var/storage/secattach/20260724/26812918.html

Jaguar Health expands crofelemer compassionate use to EU infant

Wed, 22 Jul 2026 09:01:55 -0400

Jaguar Health, Inc. (NASDAQ: JAGX) announced that its subsidiary Napo Pharmaceuticals is providing crofelemer powder for oral solution to an infant in the European Union under a compassionate use pathway for the treatment of intestinal failure due to microvillus inclusion disease (MVID).

Napo has previously supplied crofelemer to infant and pediatric patients with MVID in the U.S. under Single-Patient Investigational New Drug applications, and has also provided the drug for an investigator-initiated proof-of-concept trial in pediatric patients in the United Arab Emirates.

According to the company, the EU patient's physician became aware of crofelemer following data presentations at the 58th Annual European

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

Wed, 22 Jul 2026 09:00:00 -0400

Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID

SAN FRANCISCO, CA / ACCESS Newswire / July 22, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for treatment of intestinal failure (IF) due to microvillus inclusion disease (MVID) in an infant in the European Union (EU) for compassionate use.

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

Wed, 22 Jul 2026 09:00:00 -0400

Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID

SAN FRANCISCO, CA / ACCESS Newswire / July 22, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for treatment of intestinal failure (IF) due to microvillus inclusion disease (MVID) in an infant in the European Union (EU) for compassionate use.

Jaguar Health (JAGX) files for 5.52M share offering by selling stockholders

Thu, 16 Jul 2026 06:04:16 -0400

Jaguar Health (NASDAQ: JAGX) has filed for up to 5,522,551 share offering by selling stockholders.

Jaguar Health (JAGX) files for 5.52M share offering by selling stockholders

Thu, 16 Jul 2026 06:04:16 -0400

Jaguar Health (NASDAQ: JAGX) has filed for up to 5,522,551 share offering by selling stockholders.

Jaguar Health (JAGX) files for 40.8M share offering by selling stockholders

Thu, 16 Jul 2026 06:03:33 -0400

Jaguar Health (NASDAQ: JAGX) on Thursday filed for 40,800,000 share offering by selling stockholders.

Jaguar Health (JAGX) files for 40.8M share offering by selling stockholders

Thu, 16 Jul 2026 06:03:33 -0400

Jaguar Health (NASDAQ: JAGX) on Thursday filed for 40,800,000 share offering by selling stockholders.

Form S-1 Jaguar Health, Inc.

Thu, 16 Jul 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260716/26775808.html

Form S-1 Jaguar Health, Inc.

Thu, 16 Jul 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260716/26775808.html

Form S-1 Jaguar Health, Inc.

Thu, 16 Jul 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260716/26775811.html

Form S-1 Jaguar Health, Inc.

Thu, 16 Jul 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260716/26775811.html